Cargando…

Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project

BACKGROUND: Biomarkers such as cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) have predictive value for progression to dementia in patients with mild cognitive impairment (MCI). The pre-dementia stage takes far longer, and the interpretation of biomarker findings is particular releva...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Maurik, Ingrid S., Slot, Rosalinde E. R., Verfaillie, Sander C. J., Zwan, Marissa D., Bouwman, Femke H., Prins, Niels D., Teunissen, Charlotte E., Scheltens, Philip, Barkhof, Frederik, Wattjes, Mike P., Molinuevo, Jose Luis, Rami, Lorena, Wolfsgruber, Steffen, Peters, Oliver, Jessen, Frank, Berkhof, Johannes, van der Flier, Wiesje M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466790/ https://www.ncbi.nlm.nih.gov/pubmed/30987684 http://dx.doi.org/10.1186/s13195-019-0487-y

Ejemplares similares

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design
por: de Wilde, Arno, et al.
Publicado: (2017)

ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics
por: Fruijtier, Agnetha D., et al.
Publicado: (2019)

Clinician-patient communication during the diagnostic workup: The ABIDE project
por: Visser, Leonie N.C., et al.
Publicado: (2019)

Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project
por: Kunneman, Marleen, et al.
Publicado: (2017)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Clinicians’ communication with patients receiving a MCI diagnosis: The ABIDE project
por: Visser, Leonie N. C., et al.
Publicado: (2020)

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
por: Verfaillie, Sander C. J., et al.
Publicado: (2018)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Biomarker testing in MCI patients—deciding who to test
por: van Maurik, Ingrid S., et al.
Publicado: (2021)

Steeper memory decline after COVID-19 lockdown measures
por: Bakker, Els D., et al.
Publicado: (2023)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results
por: Slot, Rosalinde E. R., et al.
Publicado: (2018)

Computer-assisted prediction of clinical progression in the earliest stages of AD
por: Rhodius-Meester, Hanneke F.M., et al.
Publicado: (2018)

Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project
por: Kunneman, Marleen, et al.
Publicado: (2017)

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline
por: Verfaillie, Sander C.J., et al.
Publicado: (2016)

Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease
por: Mank, Arenda, et al.
Publicado: (2022)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Added value of amyloid PET in individualized risk predictions for MCI patients
por: van Maurik, Ingrid S., et al.
Publicado: (2019)

What patients want to know, and what we actually tell them: The ABIDE project
por: Fruijtier, Agnetha D., et al.
Publicado: (2020)

Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples
por: Wolfsgruber, Steffen, et al.
Publicado: (2019)

Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease
por: van Maurik, Ingrid S, et al.
Publicado: (2019)

Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer’s disease
por: Ingala, Silvia, et al.
Publicado: (2022)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project
por: Visser, Leonie N. C., et al.
Publicado: (2019)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review
por: de Wilde, Arno, et al.
Publicado: (2018)

Cerebral perfusion in the predementia stages of Alzheimer’s disease
por: Binnewijzend, Maja A. A., et al.
Publicado: (2015)

Wishes and preferences for an online lifestyle program for brain health—A mixed methods study
por: Wesselman, Linda M.P., et al.
Publicado: (2018)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial
por: Fruijtier, Agnetha D., et al.
Publicado: (2022)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis
por: Rhodius-Meester, Hanneke F. M., et al.
Publicado: (2017)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum
por: van Loenhoud, Anna C., et al.
Publicado: (2022)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Visual assessment of posterior atrophy development of a MRI rating scale
por: Koedam, Esther L. G. E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_paqib2ulmkq24s390qlf4fq97d